S. 1954Reported
Biosimilar Red Tape Elimination Act
Eliminates regulatory barriers for biosimilar biological products to streamline approval and market entry
Plain-English overview
What this bill does
Eliminates regulatory barriers for biosimilar biological products to streamline approval and market entry
Key points
- Repeal biosimilar regulatory requirements
Current status
Where it stands
Status
Reported
Latest action
2026-06-17 — Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Related context
Topics and policy areas
undefinedDrug safety, medical device, and laboratory regulationGovernment information and archivesHealthLicensing and registrationsPrescription drugs